PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Pfizer's Changing Strategy
From issue 94 of the PharmaDeals Review (2008-04-01)
Pfizer has agreed to acquire Encysive Pharmaceuticals, a publicly held biopharmaceutical company which had been open to acquisition offers since mid-2007. This article examines Encysive’s problems in the US with its lead drug candidate, Thelin® (for pulmonary arterial hypertension) and what the company has to offer Pfizer apart from this drug, and also looks at Pfizer’s recent acquisition history, its biologics strategy, and the way that the company plans to make up for the loss of revenues after Lipitor® (its best-selling anti-cholesterol drug) loses exclusivity in November 2011.
Available as PDF
(Subscribers only)
Roche - Still One Step Ahead?
From issue 94 of the PharmaDeals Review (2008-04-01)
One of the next big shifts that the pharmaceutical industry will need to adapt to is the death of the blockbuster model, with which comes the emergence of personalised healthcare. Roche has experience in this area from its development of Herceptin®, and has now, with Genentech and OSI Pharmaceuticals, allied with Abbott Laboratories to develop a test to better target cancer patients being treated with Tarceva®. This article traces the development of Tarceva, advances related to a targeted test for its use, and progress in other personalised healthcare tests to date.
Available as PDF
(Subscribers only)
Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector: a review of a recently published report
From issue 94 of the PharmaDeals Review (2008-04-01)
This article outlines a new report which has been published under the PharmaDeals imprint. It is a co-publication with Bird & Bird, and has been written by two of the partners of that firm: Richard Eccles and Gerry Kamstra. The report sets out the essential issues concerning the IP regime and the application of competition law within the pharmaceuticals sector, and the sector-specific regulatory provisions that affect competition within it. The resulting case law and related regulatory developments are central to decisions made by pharmaceuticals companies in the EU. The report also summarises the various legal issues and developments involved, with examples given from leading cases.
Available as PDF
(Subscribers only)
Therapy Focus - Type 1 Diabetes, the Latest Developments
From issue 94 of the PharmaDeals Review (2008-04-01)
Type 1 diabetes is an autoimmune disease in which insufficient insulin is produced to regulate blood glucose, and is due to loss of the insulin-producing pancreatic beta cells. This therapy focus looks at the different possible treatments that are under development for the disease – prophylactic vaccines, antibodies for prevention and treatment, and approaches to the regeneration or replacement of pancreatic beta cells – and the various deals that have been made concerning them.
Available as PDF
(Subscribers only)
Amgen Forced to Surrender Japan
From issue 93 of the PharmaDeals Review (2008-03-01)
Safety fears over Amgen’s anaemia franchise have contributed to a predicted US$1.5 B fall in revenue from its Epogen® and Aranesp® products in 2008, and the company began the painful task of cost cutting by restructuring in August 2007. Now though, it has signed a deal with Takeda Pharmaceutical worth a potential US$1.2 B. The deal saw the sale of Amgen’s Japanese subsidiary, and the granting to Takeda of the Japanese rights to 12 Amgen compounds, and of worldwide rights to an oncology compound.
Last Issue PDF
RSS